Danish Marine and Shipping Stock News

Gabriel Holding A/S ( CPH:GABR ) recently posted some strong earnings, and the market responded positively. We did some...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights Institutions' substantial holdings in H+H International implies that they have significant influence over...

In November 2025, Novo Nordisk announced that its Evoke and Evoke+ phase 3 trials found oral semaglutide did not significantly slow progression in early-stage Alzheimer's disease, prompting the company to discontinue a planned extension of the studies. This outcome marks a setback in the company's efforts to expand GLP-1-based medicines beyond diabetes and obesity into neurology, highlighting the challenges of diversifying its drug pipeline while facing increased competition in core...

Rockwool (CPSE:ROCK B) has just released its Q3 2025 results, reporting revenue of €963 million and basic EPS of €0.6, with net income (excluding extra items) at €122 million. Looking back, the company has seen revenues move from €957 million in Q3 2024 through varying quarters to €963 million this quarter. EPS has ranged between €0.54 and €0.7 per share across recent results. Margins settled somewhat from last year's levels, reflecting steady but less dynamic profitability as investors weigh...

Curious if Genmab is a bargain right now? Let’s dive into what might make this innovative biotech stock an appealing buy, or a candidate for caution. After an impressive 32.5% rally year-to-date and a 34.3% jump over the last 12 months, Genmab’s stock has been firmly in the spotlight, suggesting renewed investor optimism. Several partnership announcements and drug development milestones have fueled Genmab’s price momentum recently, with news flow focused on promising pipeline progress and...

Vestjysk Bank (CPSE:VJBA) has just posted its Q3 2025 results, recording revenue of 508.9 million DKK and net income (excluding extra items) of 196.5 million DKK. Looking back, the company has seen revenue hover in the 477 to 574 million DKK range across the last five quarters, while net income (excluding extra items) fluctuated between 173.9 million DKK and 257.9 million DKK. Investors will note that margins have compressed over the period, setting the stage for a closer look at longer-term...

TCM Group (CPSE:TCM) has just reported Q3 2025 results, posting revenue of 288.9 million DKK and basic EPS of 0.93 DKK, with net income at 9.6 million DKK for the quarter. Over the past twelve months, revenue has climbed from 1,189.4 million DKK to 1,247.5 million DKK, up 8.2% year-over-year. Net income rose from 29.8 million DKK to 66.9 million DKK, reflecting a 65.9% increase. With profit margins expanding and earnings momentum building, the latest numbers set the stage for investors to...

With a price-to-earnings (or "P/E") ratio of 17.5x Demant A/S ( CPH:DEMANT ) may be sending bearish signals at the...

Key Insights The projected fair value for PARKEN Sport & Entertainment is kr.175 based on Dividend Discount Model With...

Vestas Wind Systems A/S ( CPH:VWS ) shares have had a really impressive month, gaining 25% after a shaky period...

Key Insights Ambu's Annual General Meeting to take place on 3rd of December Salary of kr.8.01m is part of CEO Britt...

Key Insights Per Aarsleff Holding's significant retail investors ownership suggests that the key decisions are...

Novo Nordisk (CPSE:NOVO B) shares have edged slightly higher, continuing a pattern of modest moves over the past week. Investors appear to be digesting recent financial data while assessing the stock's performance in a changing market environment. See our latest analysis for Novo Nordisk. While Novo Nordisk’s share price has bounced in the last trading session, the stock is still working to rebuild momentum after a challenging stretch. Over the past year, shareholders have seen a total return...

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have experienced a downturn, with major indexes such as the STOXX Europe 600 and Germany's DAX seeing notable declines. In this environment of cautious sentiment, identifying undervalued stocks can present opportunities for investors seeking value in solid fundamentals and potential for growth despite broader market challenges.

Amidst renewed concerns over inflated AI stock valuations, the European markets have experienced a downturn, with the pan-European STOXX Europe 600 Index falling by 2.21%. As investors navigate these turbulent times, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

Scandinavian Medical Solutions A/S ( CPH:SMSMED ) last week reported its latest full-year results, which makes it a...

Nilfisk Holding A/S ( CPH:NLFSK ) just released its latest quarterly report and things are not looking great. It was a...

Pandora (CPSE:PNDORA) shares have experienced mixed trading over the past month, falling roughly 12% even as the company posted steady annual revenue and net income growth. Recent trends suggest investors are weighing current valuation against long-term performance history. See our latest analysis for Pandora. Shares of Pandora remain in the spotlight after a sharp 30-day share price return of -11.9%, which has brought the year-to-date decline to over 42%. Despite these slides, Pandora’s...

The cBrain A/S ( CPH:CBRAIN ) share price has fared very poorly over the last month, falling by a substantial 28%. The...

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...

Wondering if Novo Nordisk could be a bargain, overpriced, or hiding in plain sight? You are not alone in trying to answer that question. Let's cut through the noise together. After a wild ride including a 58.4% return over five years, the stock has dropped 11.3% in the last month and is now down 52.3% since the start of the year. This can shift how investors weigh both growth potential and risk. Recent headlines have been swirling around Novo Nordisk, with news of expanding production...

Gabriel Holding A/S ( CPH:GABR ) shareholders should be happy to see the share price up 29% in the last quarter. But...

Some FLSmidth & Co. A/S ( CPH:FLS ) shareholders may be a little concerned to see that the Group Chief Executive...